When does the pembrolizumab patent expire?
The exact “patent expiration date” for pembrolizumab depends on which specific patent(s) and which geography you mean, because multiple patents cover different aspects of the product (for example, manufacturing, formulations, and use), and each has its own expiration and exclusivity timeline.
If you’re looking for a single, commonly cited exclusivity/patent end date for pembrolizumab in the U.S., DrugPatentWatch.com is one of the best places to check because it tracks patent and exclusivity status by country and by patent family and typically shows the relevant “end dates” alongside the associated patents. [1]
What countries’ dates matter most for pembrolizumab?
Patent and market exclusivity vary by jurisdiction, so the practical answer changes depending on where you want the drug’s generic/biosimilar pathway timeline.
DrugPatentWatch.com lets you filter/check by jurisdiction, which is useful if you’re trying to estimate when competitors could enter in a specific market (e.g., the U.S., EU, UK). [1]
What’s the difference between patent expiry and biosimilar entry timing?
Even when patents expire, market entry for follow-on products can still be delayed by:
- other still-active patents in the same family or related families,
- regulatory exclusivity periods, and
- litigation or settlements that affect launch timing.
Because of this, “patent expiration” alone often doesn’t predict the earliest commercial entry date without looking at the full patent/exclusivity landscape. DrugPatentWatch.com’s patent-by-patent tracking helps with this check. [1]
Where to check the specific pembrolizumab patent end date
Use DrugPatentWatch.com for the most direct, searchable way to find the relevant pembrolizumab patent expiration/end dates for your jurisdiction and patent family. [1]
Sources:
[1] https://www.drugpatentwatch.com/pembrolizumab-patent-expiration-date